Obesity: Pathophysiology and clinical management

Current Medicinal Chemistry

Volumn 16, Issue 4, 2009, Pages 506-521

  Gurevich Panigrahi, Tatiana ^a   Panigrahi, Soumya ^b,c   Wiechec, Emilia ^d   Los, Marek ^a  

^a BioApplications Enterprises Winnipeg   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

BMI; BVT.933; Growth hormone; PRDM16; TNF

Indexed keywords

ADIPONECTIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEPRAMONE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; BENZPHETAMINE; BVT 933; C 75; CANNABINOID 1 RECEPTOR ANTAGONIST; DEXFENFLURAMINE; EPHEDRINE; FENFLURAMINE; INSULIN; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHENDIMETRAZINE; PHENTERMINE; PLACEBO; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RECOMBINANT LEPTIN; RESISTIN; RIMONABANT; SEROTONIN AGONIST; SIBUTRAMINE; SWR 0342SA; TARANABANT; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABNORMAL FECES; ADIPOCYTE; CALORIC RESTRICTION; CELL FUNCTION; CLINICAL TRIAL; CONSTIPATION; DEFECATION DISORDER; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENERGY BALANCE; ENERGY EXPENDITURE; ENVIRONMENTAL FACTOR; EUPHORIA; FECES INCONTINENCE; FLATULENCE; FOOD INTAKE; GENE MUTATION; GENETIC ANALYSIS; HEART PALPITATION; HUMAN; HYPERTENSION; INJECTION SITE INDURATION; INJECTION SITE PAIN; INSOMNIA; LIPID STORAGE; MOOD DISORDER; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TARGETING; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SIGNAL TRANSDUCTION; STEATORRHEA; STRUCTURE ANALYSIS; TACHYCARDIA; THERMOGENESIS; VALVULAR HEART DISEASE; WHITE ADIPOSE TISSUE; XEROSTOMIA; ANIMAL;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; HUMANS; OBESITY;

EID: 63449140956     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787315568     Document Type: Review

References (137)

1. Ogden, C.L.; Yanovski, S.Z.; Carroll, M.D.; Flegal, K.M. The epidemiology of obesity. Gastroenterology, 2007, 132, 2087-102.
2. Weisell, R.C. Body mass index as an indicator of obesity. Asia Pac. J. Clin. Nutr., 2002, 11(Suppl 8), S681-4.
3. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation, 2000; Vol. 894.
4. Stevens, J.; McClain, J.E.; Truesdale, K.P. Selection of measures in epidemiologic studies of the consequences of obesity. Int. J. Obes. (Lond), 2008, 32(Suppl 3), S60-6.
5. Krotkiewski, M.; Bjorntorp, P.; Sjostrom, L.; Smith, U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J. Clin. Invest., 1983, 72, 1150-62.
6. Hedley, A.A.; Ogden, C.L.; Johnson, C.L.; Carroll, M.D.; Curtin, L.R.; Flegal, K.M. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA, 2004, 291, 2847-50.
7. O'Rahilly, S.; Farooqi, I.S. Genetics of obesity. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 2006, 361, 1095-1105.
8. Chiesi, M.; Huppertz, C.; Hofbauer, K.G. Pharmacotherapy of obesity: targets and perspectives. Trends. Pharmacol. Sci., 2001, 22, 247-54.
9. Berthoud, H.R. Multiple neural systems controlling food intake and body weight. Neurosci. Biobehav. Rev., 2002, 26, 393-428.
10. Berthoud, H.R.; Morrison, C. The brain, appetite, and obesity. Annu. Rev. Psychol., 2008, 59, 55-92.
11. Friedman, J.M. The alphabet of weight control. Nature, 1997, 385, 119-20.
12. Strosberg, A.D.; Issad, T. The involvement of leptin in humans revealed by mutations in leptin and leptin receptor genes. Trends Pharmacol. Sci., 1999, 20, 227-30.
13. Fruhbeck, G.; Jebb, S.A.; Prentice, A.M. Leptin: Physiology and pathophysiology. Clin. Physiol., 1998, 18, 399-419.
14. Diamond, F.B. Jr.; Eichler, D.C. Leptin and the adipocyte endocrine system. Crit. Rev. Clin. Lab. Sci., 2002, 39, 499-525.
15. Bates, S.H.; Stearns, W.H.; Dundon, T.A.; Schubert, M.; Tso, A.W.; Wang, Y.; Banks, A.S.; Lavery, H.J.; Haq, A.K.; Maratos-Flier, E.; Neel, B.G.; Schwartz, M.W.; Myers, M.G., Jr. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature, 2003, 421, 856-9.
16. Rahmouni, K.; Haynes, W.G.; Morgan, D.A.; Mark, A.L. Intracellular mechanisms involved in leptin regulation of sympathetic outflow. Hypertension, 2003, 41, 763-7.
17. Atherton, P.J.; Babraj, J.; Smith, K.; Singh, J.; Rennie, M.J.; Wackerhage, H. Selective activation of AMPK-PGC-1alpha or PKBTSC2-mTOR signaling can explain specific adaptive responses to endurance or resistance training-like electrical muscle stimulation. FASEB J., 2005, 19, 786-8.
18. Harris, R.B.; Mitchell, T.D.; Yan, X.; Simpson, J.S.; Redmann, S.M. Jr. Metabolic responses to leptin in obese db/db mice are strain dependent. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2001, 281, R115-32.
19. Cowley, M.A. Hypothalamic melanocortin neurons integrate signals of energy state. Eur. J. Pharmacol., 2003, 480, 3-11
20. Sakurai, T.; Amemiya, A.; Ishii, M.; Matsuzaki, I.; Chemelli, R.M.; Tanaka, H.; Williams, S.C.; Richardson, J.A.; Kozlowski, G.P.; Wilson, S.; Arch, J.R.; Buckingham, R.E.; Haynes, A.C.; Carr, S.A.; Annan, R.S.; McNulty, D.E.; Liu, W.S.; Terrett, J.A.; Elshourbagy, N.A.; Bergsma, D.J.; Yanagisawa, M. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell, 1998, 92, 573-85.
21. Dulloo, A.G.; Seydoux, J.; Jacquet, J. Adaptive thermogenesis and uncoupling proteins: A reappraisal of their roles in fat metabolism and energy balance. Physiol. Behav., 2004, 83, 587-602.
22. Hosoda, H.; Kojima, M.; Kangawa, K. Ghrelin and the regulation of food intake and energy balance. Mol. Interv, 2002, 2, 494-503.
23. Hosoda, H.; Kojima, M.; Kangawa, K. Biological, physiological, and pharmacological aspects of ghrelin. J. Pharmacol. Sci., 2006, 100, 398-410.
24. Zhang, J.V.; Ren, P.G.; Avsian-Kretchmer, O.; Luo, C.W.; Rauch, R.; Klein, C.; Hsueh, A.J. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science, 2005, 310, 996-9.
25. van der Lely, A.J.; Tschop, M.; Heiman, M.L.; Ghigo, E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr. Rev., 2004, 25, 426-57.
26. Wren, A.M.; Seal, L.J.; Cohen, M.A.; Brynes, A.E.; Frost, G.S.; Murphy, K.G.; Dhillo, W.S.; Ghatei, M.A.; Bloom, S.R. Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab., 2001, 86, 5992.
27. Bachman, E.S.; Dhillon, H.; Zhang, C.Y.; Cinti, S.; Bianco, A.C.; Kobilka, B.K.; Lowell, B.B. betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science, 2002, 297, 843-5.
28. Rousset, S.; Alves-Guerra, M.C.; Mozo, J.; Miroux, B.; Cassard-Doulcier, A.M.; Bouillaud, F.; Ricquier, D. The biology of mitochondrial uncoupling proteins. Diabetes, 2004, 53(Suppl 1), S130-35.
29. Robidoux, J.; Martin, T.L.; Collins, S. Beta-adrenergic receptors and regulation of energy expenditure: A family affair. Annu. Rev. Pharmacol. Toxicol., 2004, 44, 297-323.
30. Lafontan, M.; Berlan, M. Fat cell alpha 2-adrenoceptors: The regulation of fat cell function and lipolysis. Endocr. Rev., 1995, 16, 716-38.
31. Arner, P. Catecholamine-induced lipolysis in obesity. Int. J. Obes. Relat. Metab. Disord., 1999, 23(Suppl 1), 10-13.
32. Stich, V.; De Glisezinski, I.; Crampes, F.; Hejnova, J.; Cottet-Emard, J.M.; Galitzky, J.; Lafontan, M.; Riviere, D.; Berlan, M. Activation of alpha(2)-adrenergic receptors impairs exercise-induced lipolysis in SCAT of obese subjects. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2000, 279, R499-504.
33. Lafontan, M. Fat cells: Afferent and efferent messages define new approaches to treat obesity. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 119-46.
34. Frayn, K.N. Adipose tissue as a buffer for daily lipid flux. Diabetologia, 2002, 45, 1201-10.
35. Dodt, C.; Lonnroth, P.; Fehm, H.L.; Elam, M. The subcutaneous lipolytic response to regional neural stimulation is reduced in obese women. Diabetes, 2000, 49, 1875-9.
36. Schiffelers, S.L.; Saris, W.H.; Boomsma, F.; van Baak, M.A. beta(1)- and beta(2)-Adrenoceptor-mediated thermogenesis and lipid utilization in obese and lean men. J. Clin. Endocrinol. Metab., 2001, 86, 2191-9.
37. Stahl, A.; Evans, J.G.; Pattel, S.; Hirsch, D.; Lodish, H.F. Insulin causes fatty acid transport protein translocation and enhanced fatty acid uptake in adipocytes. Dev. Cell, 2002, 2, 477-88.
38. Zierath, J.R.; Livingston, J.N.; Thorne, A.; Bolinder, J.; Reynisdottir, S.; Lonnqvist, F.; Arner, P. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: Relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia, 1998, 41, 1343-54.
39. Sengenes, C.; Bouloumie, A.; Hauner, H.; Berlan, M.; Busse, R.; Lafontan, M.; Galitzky, J. Involvement of a cGMP-dependent pathway in the natriuretic peptide-mediated hormone-sensitive lipase phosphorylation in human adipocytes. J. Biol. Chem., 2003, 278, 48617-26.
40. Yip, R.G.; Goodman, H.M. Growth hormone and dexamethasone stimulate lipolysis and activate adenylyl cyclase in rat adipocytes by selectively shifting Gi alpha2 to lower density membrane fractions. Endocrinology, 1999, 140, 1219-27.
41. Gaudiot, N.; Jaubert, A.M.; Charbonnier, E.; Sabourault, D.; Lacasa, D.; Giudicelli, Y.; Ribiere, C. Modulation of white adipose tissue lipolysis by nitric oxide. J. Biol. Chem., 1998, 273, 13475-81.
42. Bing, C.; Bao, Y.; Jenkins, J.; Sanders, P.; Manieri, M.; Cinti, S.; Tisdale, M.J.; Trayhurn, P. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc. Natl. Acad. Sci. USA, 2004, 101, 2500-5.
43. McGarry, J.D. Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes, 2002, 51, 7-18.
44. Margetic, S.; Gazzola, C.; Pegg, G.G.; Hill, R.A. Leptin: A review of its peripheral actions and interactions. Int. J. Obes. Relat. Metab. Disord., 2002, 26, 1407-33.
45. Lyngso, D.; Simonsen, L.; Bulow, J. Interleukin-6 production in human subcutaneous abdominal adipose tissue: The effect of exercise. J. Physiol., 2002, 543, 373-8.
46. Ukkola, O.; Santaniemi, M. Adiponectin: A link between excess adiposity and associated comorbidities? J. Mol. Med., 2002, 80, 696-702.
47. Ouchi, N.; Ohishi, M.; Kihara, S.; Funahashi, T.; Nakamura, T.; Nagaretani, H.; Kumada, M.; Ohashi, K.; Okamoto, Y.; Nishizawa, H.; Kishida, K.; Maeda, N.; Nagasawa, A.; Kobayashi, H.; Hiraoka, H.; Komai, N.; Kaibe, M.; Rakugi, H.; Ogihara, T.; Matsuzawa, Y. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension, 2003, 42, 231-4.
48. Hardie, D.G. Minireview: The AMP-actTvated protein kinase cascade: the key sensor of cellular energy status. Endocrinology, 2003, 144, 5179-83.
49. Steppan, C.M.; Bailey, S.T.; Bhat, S.; Brown, E.J.; Banerjee, R.R.; Wright, C.M.; Patel, H.R.; Ahima, R.S.; Lazar, M.A. The hormone resistin links obesity to diabetes. Nature, 2001, 409, 307-12.
50. Apovian, C.M.; Bigornia, S.; Mott, M.; Meyers, M.R.; Ulloor, J.; Gagua, M.; McDonnell, M.; Hess, D.; Joseph, L.; Gokce, N. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler. Thromb. Vasc. Biol., 2008, 28, 1654-9.
51. Lee, Y.H.; Pratley, R.E. The evolving role of inflammation in obesity and the metabolic syndrome. Curr. Diab. Rep., 2005, 5, 70-5.
52. Xu, H.; Barnes, G.T.; Yang, Q.; Tan, G.; Yang, D.; Chou, C.J.; Sole, J.; Nichols, A.; Ross, J.S.; Tartaglia, L.A.; Chen, H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest., 2003, 112, 1821-30.
53. van Rossum, E.F.; Nicklas, B.J.; Dennis, K.E.; Berman, D.M.; Goldberg, A.P. Leptin responses to weight loss in postmenopausal women: relationship to sex-hormone binding globulin and visceral obesity. Obes. Res., 2000, 8, 29-35.
54. Campfield, L.A.; Smith, F.J. Overview: Neurobiology of OB protein (leptin). Proc. Nutr. Soc., 1998, 57, 429-40.
55. Ahima, R.S.; Osei, S.Y. Leptin signaling. Physiol. Behav., 2004, 81, 223-41.
56. Mlinar, B.; Marc, J.; Janez, A.; Pfeifer, M. Molecular mechanisms of insulin resistance and associated diseases. Clin. Chim. Acta, 2007, 375, 20-35.
57. Casteilla, L.; Cousin, B.; Carmona, M. PPARs and Adipose Cell Plasticity. PPAR Res., 2007, 2007, 68202.
58. Rankinen, T.; Zuberi, A.; Chagnon, Y.C.; Weisnagel, S.J.; Argyropoulos, G.; Walts, B.; Perusse, L.; Bouchard, C. The human obesity gene map: The 2005 update. Obesity (Silver Spring), 2006, 14, 529-44.
59. Azuma, N.; Yoshimasa, Y.; Nishimura, H.; Yamamoto, Y.; Masuzaki, H.; Suga, J.; Shigemoto, M.; Matsuoka, N.; Tanaka, T.; Satoh, N.; Igaki, T.; Miyamoto, Y.; Itoh, H.; Yoshimasa, T.; Hosoda, K.; Nishi, S.; Nakao, K. The significance of the Trp 64 Arg mutation of the beta3-adrenergic receptor gene in impaired glucose tolerance, non-insulin-dependent diabetes mellitus, and insulin resistance in Japanese subjects. Metabolism, 1998, 47, 456-60.
60. Straczkowski, M.; Dzienis-Straczkowska, S.; Stepien, A.; Kowalska, I.; Szelachowska, M.; Kinalska, I. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J. Clin. Endocrinol. Metab., 2002, 87, 4602-6.
61. Specchia, C.; Barlera, S.; Chiodini, B.D.; Nicolis, E.B.; Farrall, M.; Peden, J.; Collins, R.; Watkins, H.; Tognoni, G.; Franzosi, M.G. Quantitative trait genetic linkage analysis of body mass index in familial coronary artery disease. Hum. Hered., 2008, 66, 19-24.
62. Jhanwar-Uniyal, M.; Beck, B.; Jhanwar, Y.S.; Burlet, C.; Leibowitz, S.F. Neuropeptide Y projection from arcuate nucleus to parvocellular division of paraventricular nucleus: Specific relation to the ingestion of carbohydrate. Brain Res., 1993, 631, 97-106.
63. Lee, M.; Korner, J. Review of physiology, clinical manifestations, and management of hypothalamic obesity in humans. Pituitary, 2008, [Epub ahead of print].
64. Weaver, J.U. Classical endocrine diseases causing obesity. Front. Horm. Res., 2008, 36, 212-28.
65. Ness-Abramof, R.; Apovian, C.M. Drug-induced weight gain. Timely Top. Med. Cardiovasc. Dis., 2005, 9, E31.
66. Mattes, R.D. Food palatability, rheology, and meal patterning. JPEN. J. Parenter. Enteral. Nutr., 2008, 32, 572-4
67. Blundell, J.E.; Gillett, A. Control of food intake in the obese. Obes. Res., 2001, 9(Suppl 4), 263S-70S.
68. Hill, J.O.; Wyatt, H.R. Role of physical activity in preventing and treating obesity. J. Appl. Physiol., 2005, 99, 765-70.
69. Ravussin, E.; Valencia, M.E.; Esparza, J.; Bennett, P.H.; Schulz, L.O. Effects of a traditional lifestyle on obesity in Pima Indians. Diabetes Care, 1994, 17, 1067-74.
70. Schulz, L.O.; Bennett, P.H.; Ravussin, E.; Kidd, J.R.; Kidd, K.K.; Esparza, J.; Valencia, M.E. Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care, 2006, 29, 1866-71.
71. Campfield, L.A.; Smith, F.J.; Burn, P. Strategies and potential molecular targets for obesity treatment. Science, 1998, 280, 1383-7.
72. Yanovski, S.Z.; Yanovski, J.A. Obesity. N. Engl. J. Med., 2002, 346, 591-602.
73. Scott, S. The Prescription, 20 ed. Baltimore MD: Lippincott Williams and Wilkins 2000.
74. Steelman, M.; Tiedt, T. Long-term pharmacotherapy in the management of obesity. National Task Force on the Prevention and Treatment of Obesity. JAMA, 1996, 276, 1907-15.
75. Steelman, M. Pharmacotherapy in the management of obesity. JAMA, 1997, 277, 1201-2; author reply 1202.
76. Guy-Grand, B. Clinical studies with dexfenfluramine: From past to future. Obes. Res., 1995, 3(Suppl 4), 491S-6S.
77. Goldstein, D.J.; Rampey, A.H. Jr.; Enas, G.G.; Potvin, J.H.; Fludzinski, L.A.; Levine, L.R. Fluoxetine: A randomized clinical trial in the treatment of obesity. Int. J. Obes. Relat. Metab. Disord., 1994, 18, 129-35.
78. Bach, D.S.; Rissanen, A.M.; Mendel, C.M.; Shepherd, G.; Weinstein, S.P.; Kelly, F.; Seaton, T.B.; Patel, B.; Pekkarinen, T.A.; Armstrong, W.F. Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes. Res., 1999, 7, 363-9.
79. James, W.P.; Astrup, A.; Finer, N.; Hilsted, J.; Kopelman, P.; Rossner, S.; Saris, W.H.; Van Gaal, L.F. Effect of sibutramine on weight maintenance after weight loss: A randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet, 2000, 356, 2119-25.
80. Padwal, R.S.; Majumdar, S.R. Drug treatments for obesity: Orlistat, sibutramine, and rimonabant. Lancet, 2007, 369, 71-7.
81. Akbas, F.; Gasteyger, C.; Sjodin, A.; Astrup, A.; Larsen, T.M. A critical review of the cannabinoid receptor as a drug target for obesity management. Obes. Rev., 2008, [Epub ahead of print].
82. Jbilo, O.; Ravinet-Trillou, C.; Arnone, M.; Buisson, I.; Bribes, E.; Peleraux, A.; Penarier, G.; Soubrie, P.; Le Fur, G.; Galiegue, S.; Casellas, P. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J., 2005, 19, 1567-9.
83. Sjostrom, L.; Rissanen, A.; Andersen, T.; Boldrin, M.; Golay, A.; Koppeschaar, H.P.; Krempf, M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet, 1998, 352, 167-72.
84. Heck, A.M.; Yanovski, J.A.; Calis, K.A. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy, 2000, 20, 270-9.
85. Davidson, M.H.; Hauptman, J.; DiGirolamo, M.; Foreyt, J.P.; Halsted, C.H.; Heber, D.; Heimburger, D.C.; Lucas, C.P.; Robbins, D.C.; Chung, J.; Heymsfield, S.B. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial. JAMA, 1999, 281, 235-42.
86. Drew, B.S.; Dixon, A.F.; Dixon, J.B. Obesity management: Update on orlistat. Vasc. Health Risk Manag., 2007, 3, 817-21.
87. MacWalter, R.S.; Fraser, H.W.; Armstrong, K.M. Orlistat enhances warfarin effect. Ann. Pharmacother., 2003, 37, 510-12.
88. Zhi, J.; Moore, R.; Kanitra, L.; Mulligan, T.E. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J. Clin. Pharmacol., 2003, 43, 428-35.
89. Zhi, J.; Moore, R.; Kanitra, L.; Mulligan, T.E. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J. Clin. Pharmacol., 2002, 42, 1011-19.
90. Stahl, A.; Hirsch, D.J.; Gimeno, R.E.; Punreddy, S.; Ge, P.; Watson, N.; Patel, S.; Kotler, M.; Raimondi, A.; Tartaglia, L.A.; Lodish, H.F. Identification of the major intestinal fatty acid transport protein. Mol. Cell, 1999, 4, 299-308.
91. Smith, S.J.; Cases, S.; Jensen, D.R.; Chen, H.C.; Sande, E.; Tow, B.; Sanan, D.A.; Raber, J.; Eckel, R.H.; Farese, R.V., Jr. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat. Genet., 2000, 25, 87-90.
92. Lowell, B.B. Adaptive thermogenesis: Turning on the heat. Curr. Biol., 1998, 8, R517-20.
93. Ribeiro, M.O.; Carvalho, S.D.; Schultz, J.J.; Chiellini, G.; Scanlan, T.S.; Bianco, A.C.; Brent, G.A. Thyroid hormone-sympathetic interaction and adaptive thermogenesis are thyroid hormone receptor isoform--specific. J. Clin. Invest., 2001, 108, 97-105.
94. Ribeiro, M.O. Effects of thyroid hormone analogs on lipid metabolism and thermogenesis. Thyroid, 2008, 18, 197-203.
95. Weyer, C.; Gautier, J.F.; Danforth, E., Jr. Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes-an update. Diabetes Metab., 1999, 25, 11-21.
96. de Souza, C.J.; Burkey, B.F. Beta 3-adrenoceptor agonists as antidiabetic and anti-obesity drugs in humans. Curr. Pharm. Des., 2001, 7, 1433-49.
97. Dow, R.L. Beta3-adrenergic agonists: Potential therapeutics for obesity. Expert Opin. Investig. Drugs, 1997, 6, 1811-25
98. Harada, H.; Hirokawa, Y.; Suzuki, K.; Hiyama, Y.; Oue, M.; Kawashima, H.; Kato, H.; Yoshida, N.; Furutani, Y.; Kato, S. Discovery of a novel and potent human and rat beta3-adrenergic receptor agonist, [3-[(2R)- (2R)-(3-chlorophenyl)-2-hydroxyethyl] amino]propyl]-1H-indol-7-y loxy]acetic acid. Chem. Pharm. Bull. (Tokyo), 2005, 53, 184-98.
99. Nedergaard, J.; Golozoubova, V.; Matthias, A.; Asadi, A.; Jacobsson, A.; Cannon, B. UCP1: The only protein able to mediate adaptive non-shivering thermogenesis and metabolic inefficiency. Biochim. Biophys. Acta, 2001, 1504, 82-106.
100. Boss, O.; Hagen, T.; Lowell, B.B. Uncoupling proteins 2 and 3: Potential regulators of mitochondrial energy metabolism. Diabetes, 2000, 49, 143-56.
101. Schrauwen, P.; Hesselink, M. UCP2 and UCP3 in muscle controlling body metabolism. J. Exp. Biol., 2002, 205, 2275-85.
102. Wu, Z.; Puigserver, P.; Spiegelman, B.M. Transcriptional activation of adipogenesis. Curr. Opin. Cell Biol., 1999, 11, 689-94.
103. Wood, J.G.; Rogina, B.; Lavu, S.; Howitz, K.; Helfand, S.L.; Tatar, M.; Sinclair, D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature, 2004, 430, 686-9.
104. Chen, D.; Guarente, L. SIR2: A potential target for calorie restriction mimetics. Trends Mol. Med., 2007, 13, 64-71.
105. Picard, F.; Kurtev, M.; Chung, N.; Topark-Ngarm, A.; Senawong, T.; Machado De Oliveira, R.; Leid, M.; McBurney, M.W.; Guarente, L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature, 2004, 429, 771-6.
106. Bordone, L.; Motta, M.C.; Picard, F.; Robinson, A.; Jhala, U.S.; Apfeld, J.; McDonagh, T.; Lemieux, M.; McBurney, M.; Szilvasi, A.; Easlon, E.J.; Lin, S.J.; Guarente, L. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol., 2006, 4, e31.
107. Rodgers, J.T.; Lerin, C.; Haas, W.; Gygi, S.P.; Spiegelman, B.M.; Puigserver, P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature, 2005, 434, 113-18.
108. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P.J.; Poosala, S.; Becker, K.G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K.W.; Spencer, R.G.; Lakatta, E.G.; Le Couteur, D.; Shaw, R.J.; Navas, P.; Puigserver, P.; Ingram, D.K.; de Cabo, R.; Sinclair, D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444, 337-42.
109. Carsten, R.E.; Bachand, A.M.; Bailey, S.M.; Ullrich, R.L. Resveratrol reduces radiation-induced chromosome aberration frequencies in mouse bone marrow cells. Radiat. Res., 2008, 169, 633-8
110. Saiko, P.; Szakmary, A.; Jaeger, W.; Szekeres, T. Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat. Res., 2008, 658, 68-94.
111. Miller, N.J.; Rice-Evans, C.A. Antioxidant activity of resveratrol in red wine. Clin. Chem., 1995, 41, 1789.
112. Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov., 2006, 5, 493-506.
113. Milne, J.C.; Lambert, P.D.; Schenk, S.; Carney, D.P.; Smith, J.J.; Gagne, D.J.; Jin, L.; Boss, O.; Perni, R.B.; Vu, C.B.; Bemis, J.E.; Xie, R.; Disch, J.S.; Ng, P.Y.; Nunes, J.J.; Lynch, A.V.; Yang, H.; Galonek, H.; Israelian, K.; Choy, W.; Iffland, A.; Lavu, S.; Medvedik, O.; Sinclair, D.A.; Olefsky, J.M.; Jirousek, M.R.; Elliott, P.J.; Westphal, C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature, 2007, 450, 712-16.
114. Scarpello, J.H.; Howlett, H.C. Metformin therapy and clinical uses. Diab. Vasc. Dis. Res., 2008, 5, 157-67.
115. Eurich, D.T.; Majumdar, S.R.; McAlister, F.A.; Tsuyuki, R.T.; Johnson, J.A. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care, 2005, 28, 2345-51.
116. Hundal, R.S.; Krssak, M.; Dufour, S.; Laurent, D.; Lebon, V.; Chandramouli, V.; Inzucchi, S.E.; Schumann, W.C.; Petersen, K.F.; Landau, B.R.; Shulman, G.I. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes, 2000, 49, 2063-9.
117. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M.F.; Goodyear, L.J.; Moller, D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest., 2001, 108, 1167-74.
118. Dhahbi, J.M.; Mote, P.L.; Fahy, G.M.; Spindler, S.R. Identification of potential caloric restriction mimetics by microarray profiling. Physiol. Genomics, 2005, 23, 343-50.
119. Ingram, D.K.; Zhu, M.; Mamczarz, J.; Zou, S.; Lane, M.A.; Roth, G.S.; deCabo, R. Calorie restriction mimetics: An emerging research field. Aging Cell, 2006, 5, 97-108.
120. Nissen, S.E.; Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med., 2007, 356, 2457-71.
121. Wan, R.; Camandola, S.; Mattson, M.P. Intermittent fasting and dietary supplementation with 2-deoxy-D-glucose improve functional and metabolic cardiovascular risk factors in rats. FASEB J., 2003, 17, 1133-4.
122. Wolf, G. Leptin: The weight-reducing plasma protein encoded by the obese gene. Nutr. Rev., 1996, 54, 91-3.
123. Kalra, S.P.; Kalra, P.S. Gene-transfer technology: A preventive neurotherapy to curb obesity, ameliorate metabolic syndrome and extend life expectancy. Trends Pharmacol. Sci., 2005, 26, 488-95.
124. Farooqi, I.S.; Jebb, S.A.; Langmack, G.; Lawrence, E.; Cheetham, C.H.; Prentice, A.M.; Hughes, I.A.; McCamish, M.A.; O'Rahilly, S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med., 1999, 341, 879-884.
125. Mantzoros, C.S.; Flier, J.S. Editorial: Leptin as a therapeutic agent-trials and tribulations. J. Clin. Endocrinol. Metab., 2000, 85, 4000-2.
126. Ettinger, M.P.; Littlejohn, T.W.; Schwartz, S.L.; Weiss, S.R.; McIlwain, H.H.; Heymsfield, S.B.; Bray, G.A.; Roberts, W.G.; Heyman, E.R.; Stambler, N.; Heshka, S.; Vicary, C.; Guler, H.P. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: A randomized, dose-ranging study. JAMA, 2003, 289, 1826-32.
127. Foster-Schubert, K.E.; Cummings, D.E. Emerging therapeutic strategies for obesity. Endocr. Rev., 2006, 27, 779-93.
128. Xu, J.; Li, L.; Qian, Z.; Hong, J.; Shen, S.; Huang, W. Reduction of PTP1B by RNAi upregulates the activity of insulin controlled fatty acid synthase promoter. Biochem. Biophys. Res. Commun., 2005, 329, 538-43.
129. Chen, X.; Matthews, J.; Zhou, L.; Pelton, P.; Liang, Y.; Xu, J.; Yang, M.; Cryan, E.; Rybczynski, P.; Demarest, K. Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist. Metabolism, 2008, 57, 1516-25.
130. Guo, Q.; Sahoo, S.P.; Wang, P.R.; Milot, D.P.; Ippolito, M.C.; Wu, M.S.; Baffic, J.; Biswas, C.; Hernandez, M.; Lam, M.H.; Sharma, N.; Han, W.; Kelly, L.J.; MacNaul, K.L.; Zhou, G.; Desai, R.; Heck, J.V.; Doebber, T.W.; Berger, J.P.; Moller, D.E.; Sparrow, C.P.; Chao, Y.S.; Wright, S.D. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology, 2004, 145, 1640-8.
131. Kasai, S.; Inoue, T.; Yoshitomi, H.; Hihara, T.; Matsuura, F.; Harada, H.; Shinoda, M.; Tanaka, I. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs. J. Pharmacol. Sci., 2008, 108, 40-8.
132. Ioannides-Demos, L.L.; Proietto, J.; Tonkin, A.M.; McNeil, J.J. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf., 2006, 29, 277-302.
133. Maddika, S.; Ande, S.R.; Panigrahi, S.; Paranjothy, T.; Weglarczyk, K.; Zuse, A.; Eshraghi, M.; Manda, K.D.; Wiechec, E.; Los, M. Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy. Drug Resist. Updat, 2007, 10, 13-29].
134. Maddika, S.; Ande, S.R.; Wiechec, E.; Hansen, L.L.; Wesselborg, S.; Los, M. Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis. J. Cell Sci., 2008, 121, 979-88.
135. Maddika, S.; Bay, G.H.; Kroczak, T.J.; Ande, S.R.; Maddika, S.; Wiechec, E.; Gibson, S.B.; Los, M. Akt is transferred to the nucleus of cells treated with apoptin, and it participates in apoptin-induced cell death. Cell Prolif., 2007, 40, 835-48.
136. Rashedi, I.; Panigrahi, S.; Ezzati, P.; Ghavami, S.; Los, M. Autoimmunity and apoptosis - therapeutic implications. Curr. Med. Chem., 2007, 14, 3139-51.
137. Seale, P.; Bjork, B.; Yang, W.; Kajimura, S.; Chin, S.; Kuang, S.; Scime, A.; Devarakonda, S.; Conroe, H.M.; Erdjument-Bromage, H.; Tempst, P.; Rudnicki, M.A.; Beier, D.R.; Spiegelman, B.M. PRDM16 controls a brown fat/skeletal muscle switch. Nature, 2008, 454, 961-7.